R&D News | pharmaphorum

News

Spero snaps up Innovent immunology drug in strategic pivot

Spero has licensed rights to an anti-CD40L antibody developed by China's Innovent, in a $1.1bn deal that signals a shift away from antimicrobial R&D.

News

AstraZeneca adds another Chinese asset, from Dizal

AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5bn licensing deal for Dizal Pharma's lung cancer therapy Zegfrovy.

News

First trial of Bundibugyo Ebola vaccine starts in UK

Oxford University has launched what it says is the world's first phase I trial of a vaccine specifically designed to protect against Bundibugyo Ebola.

News

Major trial launched to explore GLP-1 benefit in dementia

A $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar incretins can reduce the risk of dementia.

News

GSK to file Jemperli for rectal cancer after phase 3 readout

GSK's pivotal AZUR-1 trial of Jemperli monotherapy to delay or eliminate surgery in pre-operative rectal cancer has delivered a positive result.

News

Pay offer rejected as ICR researchers continue strike action

Researchers at the UK Institute of Cancer Research have held historic strikes over pay, claiming they are missing meals and struggling to cover bills.

Spero snaps up Innovent immunology drug in strategic pivot

AstraZeneca adds another Chinese asset, from Dizal

First trial of Bundibugyo Ebola vaccine starts in UK

Major trial launched to explore GLP-1 benefit in dementia

GSK to file Jemperli for rectal cancer after phase 3 readout

Pay offer rejected as ICR researchers continue strike action

Enhertu OK ends 10-year EU gap in frontline breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks